Danish Genmab inks $1.1 bn deal with Johnson & Johnson

Danish pharmaceutical group Genmab said Thursday it had reached a deal worth up to $1.1 billion (876 million euros) with US drug giant Johnson & Johnson for the rights to the cancer treatment Daratumumab.

The deal with J&J unit Janssen Biotech involves a $55 million upfront payment to Genmab and an investment of about $80 million in new Genmab shares, the Danish company said.

"Genmab could also be entitled to up to $1 billion in development, regulatory and sales milestones, in addition to tiered double digit royalties," it added.

Daratumumab is used to treat multiple myeloma, a type of bone marrow cancer, and might have potential for other cancers such as acute myeloid leukemia.

Under the terms of the agreement, Genmab will grant Janssen an exclusive worldwide license to develop and commercialise Daratumumab.

"Daratumumab is an exciting, innovative compound, and we are delighted to add it to our portfolio," Janssen's head of research and development William Hait said in a statement.

Genmab chief executive Jan van de Winkel said the deal would "significantly strengthen" his company's financial position, allowing it to keep developing other treatments.

The Danish company revised its full-year outlook as a result of the deal, raising its revenue forecast from the previously anticipated 375-400 million kroner (50-54 million euros, $63-67 million) to 435-460 million.

Genmab also cut its full-year operating loss forecast from 200-250 million kroner to 140-190 million.

add to favorites email to friend print save as pdf

Related Stories

Merck pays J&J $500mn in drug row settlement

Apr 15, 2011

Merck said Friday it has agreed to pay fellow US pharmaceutical giant Johnson & Johnson $500 million to end a two-year tussle over profit-sharing deals for two anti-inflammatory drugs.

Diabetes drugs helps boost Novo Nordisk in Q2

Aug 09, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Wind turbine maker's shares plunge 19%

Jan 04, 2012

Vestas, the world leader in the wind turbine industry, saw its share price plummet around 19 percent at the opening Wednesday, a day after issuing a profit warning.

Wind turbine maker's shares tumble on profit alert

Oct 31, 2011

Shares in Danish company Vestas, the world leader in the wind turbine industry, plunged by 20 percent on Monday after the company issued a full-year profit warning over delays on several projects.

Recommended for you

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments